Arsenite induces aquaglyceroporin 9 expression in murine livers

Environmental Research

Volumn 110, Issue 5, 2010, Pages 443-447

  Torres Avila, Manuel ^a   Leal Galicia, Perla ^a   Sánchez Peña, Luz C ^b   Del Razo, Luz M ^b   Gonsebatt, Maria E ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Aquaglyceroporin 9 expression; Arsenic; Diabetes mellitus; Murine liver

Indexed keywords

AQUAGLYCEROPORIN; ARSENITE SODIUM; CD1 ANTIGEN; MESSENGER RNA;

ARSENIC; ARSENITE; BIOACCUMULATION; BRAIN; DIABETES; RODENT; SODIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; AQUAGLYCEROPORINS; AQUAPORINS; ARSENITES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCEROL; LIVER; MALE; MICE; SODIUM COMPOUNDS; UREA;

MURINAE; MUS; RATTUS;

EID: 77953613617     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2009.08.009     Document Type: Article

References (38)

1. 1. FEBS Lett. 2003, 555:72-78.
2. Benramdane L., Accominotti M., Fanton L., Malicier D., Vallon J.J. Arsenic speciation in human organs following fatal arsenic trioxide poisoning---a case report. Clin. Chem. 1999, 45:301-306.
3. Bhattacharjee H., Carbrey J., Rosen B.P., Mukhopadhyay R. Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem. and Biophys. Res. Comm. 2004, 322:836-841.
4. Bun-ya M., Shikata K., Nakade S., Yompakdee C., Harashima S., Oshima Y. Two new genes, PHO86 and PHO87, involved in inorganic phosphate uptake in Saccharomyces cerevisiae. Curr. Genet. 1996, 29:344-351.
5. Carbrey J.M., Gorelick-Feldman D.A., Kozono D., Praetorius J., Nielsen S., Are P. Aquaglyceroporin AQP9: solute permeation and metabolic control of expression in liver. Proc. Natl. Acad. Sci. USA, 2003, 100:2945-2950.
6. Centeno J.A., Tseng C.H., Van der Voet G.B., Finkelman R.B. Global impacts of geogenic arsenic: a medical geology research case. Ambio. 2007, 36:78-81.
7. Coronado-González, Del Razo L.M., Gonzalo García-Vargas G., Sanmiguel-Salazar F., Escobedo-de la Peña J. Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ. Res. 2007, 104:383-389.
8. Devesa V., Adair B.M., Liu J., Waalkes M.P., Diwan B.A., Styblo M., Thomas D.J. Arsenicals in maternal and fetal mouse tissues after gestational exposure to arsenite. Toxicology 2006, 224:147-155.
9. García-Chávez E., Jimenez I., Segura B., Del Razo L.M. Lipid oxidative damage and distribution of inorganic arsenic and its metabolites in the rat nervous system after arsenite exposure: Influence of alpha tocopherol supplementation. Neurotoxicology 2006, 27:1024-1031.
10. Haschek W.M., Rousseaux C.G. Fundamentals of Toxicologic Pathology 1998, Academic Press, San Diego, CA, pp. 127-130.
11. Hibuse T., Maeda N., Nagasawa A., Funahashi T. Aquaporins and glycerol metabolism. Biochim. et Biophys. Acta 2006, 1758:1004-1011.
12. Hughes M.F., Kenyon E.M., Edwards B.C., Mitchell C.T., Del Razo LM., Thomas D.J. Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate. Toxicol. Appl. Pharmacol. 2003, 191:202-210.
13. Izquierdo-Vega J.A., Soto C.A., Sanchez-Peña L.C., De Vizcaya-Ruiz A., Del Razo L.M. Diabetogenic effects and pancreatic oxidative damage in rats subchronically exposed to arsenite. Toxicol. Lett. 2006, 160:135-142.
14. Kenyon E.M., Del Razo L.M., Hughes M.F. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate. Toxicol. Sci. 2005, 85:468-475.
15. Kenyon E.M., Hughes M.F., Adair B.M., Highfill J.H., Crecelius E.A., Clewell H.J., Yager J.W. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water. Toxicol. Appl. Pharmacol. 2008, 232:448-455.
16. Kumagai Y., Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu. Rev. Pharmacol. Toxicol. 2007, 47:243-262.
17. Kuriyama H., Kawamoto S., Ishida N., Ohno I., Mita S., Matsuzawa Y., Matsubara K., Okubo K. Molecular cloning and expression of a novel human aquaporin from adipose tissue with glycerol permeability. Biochem. Biophys. Res. Comm. 1997, 241:53-58.
18. Kuriyama H., Shimomura I., Kishida K., Kondo H., Furuyama N., Nishizawa H., Maeda N., Matsuda M., Nagaretani H., Kihara S., Nakamura T., Tochino Y., Funahashi T., Matsuzawa Y. Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes 2002, 51:2915-2921.
19. Liu J., Waalkes M.P. Liver is a Target of Arsenic Carcinogenesis. Toxicol. Sci. 2008, 105:24-32.
20. Liu Z., Carbrey J.M., Agre P., Rosen P.B. Arsenic trioxide uptake by human and rat aquaglyceroporins. Biochem. Biophys. Res. Comm. 2004, 316:1178-1185.
21. Liu Z., Shen J., .Carbrey J.M., Mukhopadhyay R., Agre P., Rosen B.P. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. USA. 2002, 99:6053-6058.
22. Liu Z., Styblo M., Rosen B.P. Methylarsonous acid transport by aquaglyceroporins. Environ. Health Perspect. 2006, 114:527-531.
23. Mandal B.K., Suzuki K.T. Arsenic round the world: a review. Talanta 2002, 58:201-235.
24. Marinelli R.A., Gradilone S.A., Carreras F.I., Calamita G., Lehmann G.L. Liver aquaporins: Significance in canalicular and ductal bile formation. Annals of Hepatol. 2004, 3:130-136.
25. Miao Z.F., Chang E.E., Tsai F.Y., Yeh S.C., Wu C.F., Wu K.Y., Wang C.J., Tsou T.C. Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells. Toxicol. In Vitro 2009, 23:209-216.
26. Neiger R.D., Osweiler G.D. Arsenic concentrations in tissues and body fluids of dogs on chronic low-level dietary sodium arsenite. J. Vet. Diagn. Invest. 1992, 4:334-337.
27. Paul D.S., Hernández-Zavala A., Walton F.S., Adair B.M., Dedina J., Matousek T., Stýblo M. Examination of the effects of arsenic on glucose homeostasis in cell culture and animal studies: development of a mouse model for arsenic-induced diabetes. Toxicol. Appl. Pharmacol. 2007, 222:305-314.
28. Rodríguez V.M., Del Razo L.M., Limon-Pacheco J.H., Giordano M., Sanchez-Peña L.C., Uribe-Querol E., Gutierrez-Ospina G., Gonsebatt M.E. Glutathione reductase inhibition and methylated arsenic distribution in Cd1 mice brain and liver. Toxicol. Sci. 2005, 84:157-166.
29. Rojek A.M., Skowronski M.T., Fuchtbauer E.M., Fuchtbauer A.C., Fenton R.A., Agre P., Frokiaer J., Nielsen S. Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. Proc. Natl. Acad. Sci. 2007, 104:3609-3614.
30. Rosenberg H., Gerdes R.G., Chegwidden K. Two systems for the uptake of phosphate in Escherichia coli. J. Bacteriol. 1977, 131:505-511.
31. Sanders O.I., Rensing C., Kuroda M., Mitra B., Rosen B.P. Antimonite is accumulated by the glycerol facilitator GlpF in Escherichia coli. J. Bacteriol. 1997, 179:3365-3367.
32. Shinkai Y., Sumi D., Toyama T., Kaji T., Kumagai Y. Role of aquaporin 9 in cellular accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes. Toxicol. Appl. Pharmacol. 2009, 237:232-236.
33. Thomas D.J. Molecular processes in cellular arsenic metabolism. Toxicol. Appl. Pharmacol. 2007, 222:365-373.
34. Tsukaguchi H., Shayakul C., Berger U.V., Mackenzie B., Devidasi S., Gugginoi W.B., van Hoek A.N., Hediger M.A. Molecular characterization of a broad selectivity neutral solute channel. J. Biol. Chem. 1998, 273:24737-24743.
35. Tsukaguchi H., Weremowicz S., Morton C.C., Hediger M.A. Functional and molecular characterization of the human neutral solute channel aquaporin-9. Am. J. Physiol. 1999, 277:F685-696.
36. Waters S.B., Devesa V., Del Razo L.M., Styblo M., Thomas D.J. Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Chem. Res. Toxicol. 2004, 17:404-409.
37. Walton F.S., Harmon A.W., Paul D.S., Drobna Z., Patel Y.M., Styblo M. Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetes. Toxicol. Appl. Pharmacol. 2004, 198:424-433.
38. Wysocki R., Chery C.C., Wawrzycka D., Van Hulle M., Cornelis R., Thevelein J.M., Tamas M.J. The glycerol channel Fps1p mediates the uptake of arsenite and antimonite in Saccharomyces cerevisiae. Mol. Microbiol. 2001, 40:1391-1401.